Evidence map›Paper›PMID 39264262›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Engineered Macrophage Membrane-Coated S100A9-siRNA for Ameliorating Myocardial Ischemia-Reperfusion Injury.

He Lu, Junzhuo Wang, Ziwei Chen, Jing Wang, Yaohui Jiang, Zequn Xia, Ya Hou, Pingping Shang, Rutian Li, Yuyong Liu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

He LuNanjing Drum Tower Hospital, Drum Tower Clinical College, Nanjing University of Chinese Medicine, No. 321 Zhongshan Road, Nanjing, 210008, China.
Junzhuo WangNanjing Drum Tower Hospital, Drum Tower Clinical College, Nanjing University of Chinese Medicine, No. 321 Zhongshan Road, Nanjing, 210008, China.
Ziwei ChenDepartment of Cardiology, Affiliated Hospital of Nantong University, Nantong, 226001, China.
Jing WangNanjing Drum Tower Hospital, Drum Tower Clinical College, Nanjing University of Chinese Medicine, No. 321 Zhongshan Road, Nanjing, 210008, China.
Yaohui JiangNanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, No. 321 Zhongshan Road, Nanjing, 210008, China.
Zequn XiaNanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, No. 321 Zhongshan Road, Nanjing, 210008, China.
Ya HouNanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, No. 321 Zhongshan Road, Nanjing, 210008, China.
Pingping ShangDepartment of Cardiology, The People's Hospital of Jiawang District of Xuzhou, Xuzhou, 221011, China.
Rutian LiDepartment of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, No. 321 Zhongshan Road, Nanjing, 210008, China.
Yuyong LiuDepartment of Cardiac Surgery, National Cardiovascular Disease Regional Center for Anhui, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Jun XieNanjing Drum Tower Hospital, Drum Tower Clinical College, Nanjing University of Chinese Medicine, No. 321 Zhongshan Road, Nanjing, 210008, China.ORCID 0000-0002-9385-3242

Funding

Natural Science Foundation of China 82370305Natural Science Foundation of China 82470282Natural Science Foundation of China 92068116Science Fund for Distinguished Young Scholars in Jiangsu Province BK20211501
6 · The paper itself

Abstract

Despite the widespread adoption of emergency coronary reperfusion therapy, reperfusion-induced myocardial injury remains a challenging issue in clinical practice. Following myocardial reperfusion, S100A8/A9 molecules are considered pivotal in initiating and regulating tissue inflammatory damage. Effectively reducing the S100A8/A9 level in ischemic myocardial tissue holds significant therapeutic value in salvaging damaged myocardium. In this study, HA (hemagglutinin)- and RAGE (receptor for advanced glycation end products)- comodified macrophage membrane-coated siRNA nanoparticles (MMM/RNA NPs) with siRNA targeting S100A9 (S100A9-siRNA) are successfully prepared. This nanocarrier system is able to target effectively the injured myocardium in an inflammatory environment while evading digestive damage by lysosomes. In vivo, migration of MMM/RNA NPs to myocardial injury lesions is confirmed in a myocardial ischemia-reperfusion injury (MIRI) mouse model. Intravenous injection of MMM/RNA NPs significantly reduced S100A9 levels in serum and myocardial tissues, further decreasing myocardial infarction area and improving cardiac function. Targeted reduction of S100A8/A9 by genetically modified macrophage membrane-coated nanoparticles may represent a new therapeutic intervention for MIRI.

Indexed as

Calgranulin BDisease Models, AnimalMacrophagesMyocardial Reperfusion InjuryRNA, Small InterferingAnimalsMaleMiceMice, Inbred C57BLNanoparticlesCalgranulin BRNA, Small Interferingengineered macrophage membranemyocardial ischemia‐reperfusion injuryneutrophilsS100A8 / A9siRNA

Identifiers

PMID39264262
PMCPMC11538685

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.